

Q1 2022 Earnings Results Review



April 27, 2022

Forward-Looking Statements

• Today's presentation includes forward-looking statements that reflect Bunge's current views with respect to future events, financial performance and industry conditions.

• These forward-looking statements are subject to various risks and uncertainties. Bunge has provided additional information in its reports on file with the Securities and Exchange Commission concerning factors that could cause actual results to differ materially from those contained in this presentation and encourages you to review these factors.



Agenda

- CEO Comments
- Financial Performance
- Closing Remarks
- Q&A



Q1 Highlights and Outlook

- Continued to build on positive momentum across all segments
 - Agribusiness continues to demonstrate agility in dynamic, rapidly changing market conditions
 - Refined and Specialty Oils benefiting from favorable demand trends, as well as supply chain and innovation capabilities
 - Milling results higher, as team effectively managed the supply chain
 - Announced commercial partnership with CoverCress
- Increasing outlook to at least \$11.50 per share for full year 2022
- Actively supporting our Ukrainian colleagues



Bunge Limited Earnings Highlights

		March 31,	
(US\$ in millions, except per share data)	2022		2021
Net income per common share-diluted	\$ 4.48	\$	5.52
Adjusted Net income per common share-diluted (a)	\$ 4.26	\$	3.13
Adjusted Core Segment EBIT (a) (b)	\$ 858	\$	737
Agribusiness (c)	\$ 627	\$	601
Processing	461		363
Merchandising	166		238
Refined and Specialty Oils	180		124
Milling	51		12
Adjusted Corporate and Other EBIT (a) (d)	\$ (92)	\$	(86)
Adjusted Non-Core Segment EBIT (a) (b)	\$ 34	\$	20

Quarter Ended

d) Corporate and Other includes salaries and overhead for corporate functions that are not allocated to the Company's individual business segments, as well as certain other activities including Bunge Ventures and the Company's captive insurance and securitization activities.



a) Adjusted Net income attributable to Bunge common shareholders – diluted, Adjusted Core Segment EBIT, Adjusted Corporate and Other EBIT, and Adjusted Non-Core Segment EBIT are non-GAAP financial measures. Reconciliations to the most directly comparable U.S. GAAP measures are included in the appendix attached to this slide presentation posted on Bunge's website.


b) Core Segments comprise our Agribusiness, Refined and Specialty Oils, and Milling reportable segments. Non-Core Segment comprises our Sugar and Bioenergy reportable segment.

c) Agribusiness segment is comprised of Processing and Merchandising businesses. See appendix attached to this slide presentation posted on Bunge's website for descriptions of the Processing and Merchandising businesses.

Positive Earnings Trend

Ten consecutive quarters of increased earnings

Bunge Performance 2018 – Q1 2022 TTM






Disciplined Cost Management


Q1 2022 Adjusted Addressable SG&A savings ~flat vs. PY

- Q1 SG&A increase of \$2M
 vs PY
- \$34M net cost impact from specified items including performance-based pay, FX, inflation, and changes in portfolio





Generating Cash Flow to Drive Shareholder Value






RMI Continues to Exceed Net Debt

At Q1 quarter end, RMI (Readily Marketable Inventories) exceeded Net Debt by

\$2.8 billion





Liquidity Position Remains Strong

Bunge has committed credit facilities of ~\$5.8 billion, of which ~\$5 billion was unused and available as of March 31, 2022

In \$'millions

Facility	Maturity	Size	Amount Drawn ⁽¹⁾
364-day RCF	Jul 2022	1,000	100
5-year CoBank & Farm Credit System RCF	Oct 2026	865	0
3-year European RCF	Dec 2024	1,750	550
5-year US RCF	Jul 2026	1,350	0
5- year CP Program / CP liquidity backstop	Jul 2026	600	205
1yr Delay Draw 7-yr Term Loan	Oct 2028 ²	250	0
Total Committed Liquidity		5,815	855




While the facilities themselves are available on a committed basis through the respective maturity date, individual borrowings set up under the facilities typically average between 15 to 90 days.
 Oct-2022 is the expiry of the 1yr Delay Draw Option the Term Loan once drawn will mature in Oct-2028.

Increased Earnings Driving Higher Returns

AROIC captures benefits of earnings driven from utilization of additional working capital

Bunge Limited Returns (excluding Sugar & Bioenergy)



⁽¹⁾ Bunge WACC is at 6.0%.

⁽⁵⁾ CTA Adjustments were made for 2019 onward periods. CTA adjustment is the difference between the Cumulative Foreign Exchange Translation Adjustment balances at the current balance sheet date and December 31, 2018. To reduce the impact of foreign currency movements on book value of equity, CTA was held constant starting at 12.31.2018 for 2019 periods onwards. Details are provided in the appendix.



⁽²⁾ AWACC includes adjustments for RMI.


⁽³⁾ AROIC includes adjustments for timing differences, CTA, and RMI. Details are provided in the appendix.

⁽⁴⁾ ROIC Includes adjustments for timing differences and CTA. Details are provided in the appendix.

Increased Earnings Reflected in Discretionary Cash Flow

Bunge Performance 2018 – 2022

Discretionary Cash Flow (1,2)





(\$ millions)

⁽¹⁾ To reduce the impact of foreign currency movements on book value of equity, CTA was held constant at 12.31.2018 levels for periods commencing 2019 onwards.

Full-Year 2022 Outlook

Increasing FY2022 adjusted EPS to at least \$11.50 per share based on the following expectations:

- Agribusiness: Down vs. 2021
 - Increasing forecast from prior outlook reflecting strong Q1 performance
 - Upside potential if strong demand and tight crop supplies continue
- Refined and Specialty Oils: Up vs. 2021
 - Increasing forecast from prior outlook reflecting positive demand trends from food and fuel, particularly in North America and Europe
- Milling: Up vs 2021
 - Increasing forecast from prior outlook reflecting strong Q1 performance
- Corporate and Other: Favorable vs 2021
 - Increasing forecast from prior outlook reflecting lower variable compensation
- Non-Core Sugar and Bioenergy JV: In line with 2021
- Other Items:
 - Tax rate of 16% to 18%; net interest expense of \$250 to \$270M; capex of \$650 to \$750M; and depreciation & amortization of ~\$420M



Closing Remarks

- Resilient team has remained committed to helping customers solve problems through unprecedented volatility over last three years
- Expect continued volatility as result of uncertainty around:
 - War in Ukraine
 - Crop production levels
 - Government policy reactions
 - COVID resurgence
- Will continue to be nimble and disciplined as we invest in growth opportunities





Agribusiness: Processing and Merchandising Definitions

Processing

- Oilseed origination
 - Oilseed purchasing, cleaning, drying, storing and handling
- Oilseed processing
 - Soybean: U.S., South America, Europe,
 Asia
 - Rapeseed/Canola: Europe, Canada
 - Sunseed: Eastern Europe, Argentina
- Oilseed trading & distribution
 - Global trading and distribution of oilseeds, protein meals and vegetable oils
- Fertilizer production and distribution
- Biodiesel production (partially JVs)

Merchandising

- Grain origination
 - Grains (corn, wheat, barley) purchasing, cleaning, drying, storing and handling
- Grain trading & distribution
 - Global trading and distribution of grains and oils
- Related services
 - Ocean freight
 - Financial services



Core Segment Volume Highlights

	Quarter E March 3	
In thousands of metric tons	2022	2021
Agribusiness	20,071	21,644
Processing	10,774	11,116
Merchandising	9,297	10,528
Refined and Specialty Oils	2,295	2,176
Milling	1,161	1,041



This presentation contains certain "non-GAAP financial measures" as defined in Regulation G of the Securities Exchange Act of 1934. Bunge has reconciled these non-GAAP financial measures to the most directly comparable U.S. GAAP measures in the following slides. These measures may not be comparable to similarly titled measures used by other companies.

Operating results

To facilitate a comparison of Bunge's historical operating results and related trends, Bunge uses the accompanying non-GAAP financial measures:

- Segment EBIT, Core Segment EBIT, Non-core Segment EBIT, and Total Segment EBIT
- Adjusted Segment EBIT, Adjusted Core Segment EBIT, Adjusted Non-core Segment EBIT, and Adjusted Total Segment EBIT
- Adjusted Net Income (loss) attributable to Bunge
- Adjusted Net income (loss) per common share diluted

Bunge uses segment earnings before interest and tax ("Segment EBIT") to evaluate the operating performance of its individual segments. Segment EBIT excludes EBIT attributable to noncontrolling interests. Bunge also uses Core Segment EBIT, Non-Core Segment EBIT and Total Segment EBIT to evaluate the operating performance of Bunge's Core reportable segments, Non-Core reportable segments and Total reportable segments, together with our Corporate and Other activities, respectively. Core Segment EBIT is the aggregate of the earnings before interest and taxes of each of Bunge's Agribusiness, Refined and Specialty Oils, and Milling segments. Non-Core Segment EBIT is the earnings before interest and taxes of Bunge's Sugar & Bioenergy segment. Total Segment EBIT is the aggregate of the earnings before interest and taxes of Bunge's Core and Non-Core reportable segments, together with its Corporate and Other activities.



Adjusted Core Segment EBIT, Adjusted Non-Core Segment EBIT, and Adjusted Total Segment EBIT, are calculated by excluding certain gains and (charges), as described in "Additional Financial Information" of Bunge's accompanying quarterly earnings press release, as well as certain mark-to-market timing differences as defined in note 3 of Bunge's accompanying quarterly earnings press release, from Core Segment EBIT, Non-Core Segment EBIT and Total Segment EBIT, respectively.

Total Segment EBIT and Adjusted Total Segment EBIT are non-GAAP financial measures that are not intended to replace Net income (loss) attributable to Bunge, the most directly comparable U.S. GAAP financial measure. Bunge management believes these non-GAAP measures are a useful measure of its reportable segments' operating profitability, since the measures allow for an evaluation of segment performance without regard to their financing methods or capital structure. For this reason, operating performance measures such as these non-GAAP measures are widely used by analysts and investors in Bunge's industries. These non-GAAP measures are not a measure of consolidated operating results under U.S. GAAP and should not be considered as an alternative to net income (loss) or any other measure of consolidated operating results under U.S. GAAP. Adjusted Total Segment EBIT, Adjusted Net Income (loss) attributable to Bunge, and Adjusted Net income (loss) per common share – diluted are calculated by excluding from Total Segment EBIT, Net Income (loss) attributable to Bunge, and Net income (loss) per common share-diluted, certain gains and charges, and temporary mark-to-market timing differences as defined in Note 3 of Bunge's accompanying quarterly earnings press release.



Projected adjusted net income per common share for 2022 has also been presented. This information is provided only on a non-GAAP basis without reconciliation to projected net income per common share for 2022, the mostly directly comparable GAAP measure, due to the inability at this time to quantify certain amounts necessary for such reconciliation, including but not limited to future market price movements over the remainder of the year.

Bunge management believes presentation of these measures allows investors to view its performance using the same measures that management uses in evaluating financial and business performance and trends without regard to certain gains and charges and mark-to-market timing impacts. These non-GAAP measures are not a measure of consolidated operating results under U.S. GAAP and should not be considered as an alternative to net income (loss), net income (loss) per common share, or any other measure of consolidated operating results under U.S. GAAP.



Cash Flows

To facilitate a comparison of Bunge's historical cash flow generation and related trends, Bunge uses the following non-GAAP financial measures:

- Adjusted Funds from Operations (Adjusted FFO)
- Discretionary Cash Flow
- Cash Flow Yield

Adjusted FFO is calculated by excluding from Cash provided by (used for) operating activities, foreign exchange gain (loss) on net debt, net income attributable to non-controlling interests and redeemable noncontrolling interests, after-tax mark-to-market timing differences, and working capital changes. Discretionary Cash Flow is, in turn calculated by further deducting sustaining Capex, and dividends on Convertible perpetual preference shares from Adjusted FFO. Cash Flow Yield is calculated by dividing Discretionary Cash Flow by Book equity, which itself is calculated by deducting from Total Equity, Non-controlling interests, after-tax mark-to-market timing differences, and for periods presented since December 31, 2018, adding cumulative translation gains and losses since December 31, 2018.

Adjusted FFO, Discretionary Cash Flow, and Cash Flow Yield are non-GAAP financial measures and are not intended to replace Cash provided by (used for) operating activities, the most directly comparable U.S. GAAP financial measure. Bunge management believes presentation of these measures allows investors to view its cash generating performance using the same measures that management uses in evaluating financial and business performance and trends without regard to foreign exchange gains and losses, working capital changes and mark-to-market timing impacts. These non-GAAP measures are not a measure of consolidated cash flow under U.S. GAAP and should not be considered as an alternative to Cash provided by (used for) operating activities, Net increase (decrease) in cash and cash equivalents and restricted cash, or any other measure of consolidated cash flow under U.S. GAAP.

Book equity is a non-GAAP financial measure and is not intended to replace Total Equity, the most directly comparable U.S. GAAP financial measure. This non-GAAP measure is not a measure of consolidated equity under U.S. GAAP and should not be considered as an alternative to Total equity, Total Bunge shareholders' equity, or any other measure of consolidated cash flow under U.S. GAAP.



Returns on Capital

To facilitate a comparison of Bunge's historical returns on capital and related trends, Bunge uses the following non-GAAP financial measures:

- Return on Invested Capital (ROIC)
- Adjusted Return on Invested Capital (AROIC)

Bunge calculates ROIC by dividing Adjusted return after income tax by the quarter ended average total capital for the trailing four quarters preceding the reporting date. Adjusted Return after income tax is calculated as income from continuing operations before income tax, including noncontrolling interest, for each of the trailing four quarters, excluding interest expense, certain gains & charges as described in "Additional Financial Information" of Bunge's accompanying quarterly earnings press release, as well as certain mark-to-market timing differences as defined in note 3 of Bunge's accompanying quarterly earnings press release, times the effective tax rates for those periods. Average total capital is calculated by averaging the totals of the ending shareholders equity, noncontrolling interest and total debt balances for each quarterly period. Bunge believes that ROIC provides investors with a measure of the return the company generates on the capital invested in its business. ROIC is not a measure of financial performance under US GAAP and should not be considered in isolation or as an alternative to net income as an indicator of company performance or as an alternative to cash flows from operating activities as a measure of liquidity.

Bunge calculates AROIC by dividing Adjusted Return after income tax, excluding the funding cost of readily marketable inventories available for merchandizing activities (RMI), by the quarter ended average total capital, excluding RMI, for the trailing four quarters preceding the reporting date. Adjusted Return after income tax, excluding RMI, is calculated as income from continuing operations before income tax, including noncontrolling interest, for each of the trailing four quarters, excluding interest expense, certain gains and charges, mark-to-market timing differences, and the cost of debt used to finance RMI, times the effective tax rates for those periods. Average total capital, adjusted is calculated by averaging the totals of the ending balances of shareholders equity, noncontrolling interest and total debt less RMI available for merchandizing activities for each quarterly period. Bunge believes that AROIC provides investors with a measure of the return the company generates on the capital invested in its operating assets excluding RMI, which expands or contracts based on seasonality, commodity price cycles and market opportunities. AROIC is not a measure of financial performance under US GAAP and should not be considered in isolation or as an alternative to net income as an indicator of company performance or as an alternative to cash flows from operating activities as a measure of liquidity.

Net income (loss) attributable to Bunge to Adjusted Net income (loss)

	Marc	ch 31,
(US\$ in millions)	2022	2021
Net income (loss) attributable to Bunge	\$688	\$831
Adjustment for Mark-to-market timing difference	(62)	(195)
Adjusted for certain (gains) and charges:		
Ukraine-Russia conflict	10	-
Pension settlement	(21)	-
Bond early redemption	39	-
Gain on sales of assets		(165)
Adjusted Net income (loss) available for common shareholders	\$654	\$471
Weighted-average common shares outstanding – diluted, adjusted (1)	154	151
Adjusted Net income (loss) per common share - diluted	\$4.26	\$3.13

Quarter Ended

⁽¹⁾ Approximately zero and 2 million outstanding stock options and contingently issuable restricted stock units were not dilutive and not included in the weighted-average number of common shares outstanding for the quarters ended March 31, 2022 and 2021, respectively.



Net income (loss) attributable to Bunge to Total Segment EBIT and Adjusted Total Segment EBIT

Quarter	Ended
March	1 31,

(US\$ in millions)	2022	2021
Net income (loss) attributable to Bunge	\$688	\$831
Interest income	(9)	(9)
Interest expense	111	73
Income tax expense (benefit)	108	192
Noncontrolling interest share of interest and tax	(5)	(1)
Total Segment EBIT	\$893	\$1,086
Agribusiness EBIT	\$699	\$836
Refined and Specialty Oils EBIT	173	308
Milling EBIT	50	8
Core Segment EBIT	\$922	\$1,152
Corporate and Other EBIT	\$(63)	\$(86)
Sugar & Bioenergy EBIT	\$34	\$20
Non-Core Segment EBIT	\$34	\$20
Total Segment EBIT	\$893	\$1,086
Mark-to-market timing difference	(76)	(245)
Certain (gains) & charges	(17)	(170)
Adjusted Total Segment EBIT	\$800	\$671



Cash provided by (used for) operating activities to Adjusted FFO and Discretionary Cash Flow

US\$ in millions	2022 Q1 YTD	2022 Q1 TTM (1)	2021	2020	2019	2018
Cash provided by (used for) operating activities	(\$2,656)	(\$4,563)	(\$2,894)	(\$3,535)	(\$808)	(\$1,264)
Foreign exchange (loss) gain on net debt	\$116	\$13	(\$78)	\$206	(\$139)	(\$139)
Beneficial interest in securitized trade receivables	\$1,637	\$7,014	\$5,376	\$2,015	\$1,289	\$1,909
Working capital changes	\$1,669	(\$477)	(\$369)	\$3,082	\$714	\$583
Net (income) loss attributable to noncontrolling interests and redeemable noncontrolling interests	(\$8)	(\$11)	(\$89)	(\$20)	\$10	(\$20)
Mark-to-Market timing difference, after tax	(\$62)	\$145	\$12	\$138	\$30	(\$3)
Adjusted FFO, timing adjusted	\$696	\$2,121	\$1,958	\$1,886	\$1,096	\$1,066
Sustaining CAPEX		(\$245)	(\$226)	(\$254)	(\$341)	(\$283)
Discretionary Cash Flow (1)		\$1,876	\$1,732	\$1,632	\$755	\$783
Total Equity		\$8,741	\$7,824	\$6,205	\$6,031	\$6,377
Noncontrolling interests		(\$160)	(\$156)	(\$136)	(\$118)	(\$204)
Mark-to-Market timing difference, after tax		\$145	\$12	\$138	\$29	(\$3)
CTA Adjustments ⁽²⁾		\$555	\$950	\$707	\$119	\$0
Adjusted Book Equity (CTA adj.)		\$9,281	\$8,630	\$6,914	\$6,061	\$6,170
Cash Flow Yield (1)		20.2%	20.1%	23.6%	12.4%	12.7%

⁽¹⁾ During the first quarter of 2022, the Company's convertible preferred shares were converted to common shares. For comparability, prior periods have been recast as if the conversion had already occurred. Refer to Bunge's press release dated March 18, 2022 for further information.

BÜNGE

⁽²⁾ To reduce the impact of foreign currency movements on the book value of equity, CTA was held constant starting at December 31, 2018 levels. As such, for 2019 periods onwards, a CTA Adjustment comprising the difference between Bunge's Cumulative Foreign Exchange Translation Adjustment (CTA) balance at the period end date, and that at December 31, 2018, was applied.

Return on Invested Capital excluding certain gains and charges, mark-to-market timing differences and Sugar & Bioenergy Segment

	Trailing 4				
	Quarters	Quarters	Quarters	Quarters	Quarters
	31-Mar-22	31-Dec-21	31-Dec-20	31-Dec-19	31-Dec-18
(US\$ in millions)					
EBIT, excluding Sugar & Bioenergy	\$2,341	\$2,549	\$1,719	\$732	\$872
EBIT attributable to noncontrolling interest	25	99	23	(6)	27
Interest income	48	48	22	31	31
Certain gains & charges ⁽¹⁾	30	(176)	(64)	350	114
Mark-to-Market timing difference	161	(8)	190	35	(4)
Adjusted Return before income tax	\$2,605	\$2,512	\$1,890	\$1,142	\$1,040
Taxes ⁽²⁾	(405)	(414)	(316)	(192)	(229)
Adjusted Return after income tax	\$2,200	\$2,098	\$1,574	\$950	\$811
Trailing 4 Quarters					
Average total capital	\$14,593	\$14,320	\$11,872	\$11,597	\$12,467
Mark-to-Market timing difference adjustments (3)	11	(25)	48	35	(4)
Average total capital, adjusted	\$14,604	\$14,295	\$11,920	\$11,632	\$12,463
CTA Adjustments	746	846	941	89	
Average total capital, adjusted (CTA adj.)	\$15,350	\$15,141	\$12,861	\$11,721	\$12,463
ROIC (CTA adj.)	14.4%	13.9%	12.2%	8.1%	6.5%

⁽¹⁾ Certain gains & charges excludes certain gains and charges related to the Sugar & Bioenergy segment for all years presented and reflects 100% shareholding, i.e., including amounts attributable to noncontrolling interests.

⁽³⁾ From December 31, 2020 onwards, adjustments are based on the average of quarter-end mark-to-market timing differences. Prior adjustments are based on total Trailing 4 Quarters Mark-to-Market timing difference.



⁽²⁾ Adjusted for certain gains & charges, mark-to-market timing difference, and taxes on interest expense.

Return on Invested Capital excluding certain gains and charges, mark-to-market timing differences, RMI attributable to merchandising, and Sugar & Bioenergy Segment

	Trailing 4 Quarters 31-Mar-22	Trailing 4 Quarters 31-Dec-21	Trailing 4 Quarters 31-Dec-20	Trailing 4 Quarters 31-Dec-19	Trailing 4 Quarters 31-Dec-18
(US\$ in millions)	31-IVIGI-22	31-Dec-21	31-Dec-20	31-Dec-19	31-Dec-10
EBIT, excluding Sugar & Bioenergy	\$2,341	\$2,549	\$1,719	\$732	\$872
EBIT attributable to noncontrolling interest	25	99	23	(6)	27
Interest income	48	48	22	31	31
Certain gains & charges (1)	30	(176)	(64)	350	114
Mark-to-Market timing difference	161	(8)	190	35	(4)
Return before income tax, adjusted	\$2,605	\$2,512	\$1,890	\$1,142	\$1,040
RMI attributable to merchandising (2)	(5,523)	(5,237)	(3,865)	(3,140)	(4,039)
Cost of Debt	3.00%	3.00%	4.50%	4.50%	4.50%
RMI Adjustment	(166)	(157)	(174)	(141)	(182)
Adjusted Return before income tax	\$2,439	\$2,355	\$1,716	\$1,001	\$858
Taxes (3)	(379)	(388)	(289)	(168)	(189)
Return after income tax, adjusted	\$2,060	\$1,967	\$1,427	\$833	\$669
Trailing 4 Quarters					
Average total capital	\$14,593	\$14,320	\$11,872	\$11,597	\$12,467
Mark-to-Market timing difference adjustments (4)	11	(25)	48	35	(4)
CTA Adjustments	746	846	941	89	-
RMI attributable to merchandising (2)	(5,523)	(5,237)	(3,865)	(3,140)	(4,039)
Average total capital, adjusted	\$9,827	\$9,904	\$8,996	\$8,581	\$8,424
AROIC	21.0%	19.9%	15.9%	9.7%	7.9%

⁽¹⁾ Certain gains & charges excludes certain gains and charges related to the Sugar & Bioenergy segment for all years presented and reflects 100% shareholding, i.e., including amounts attributable to noncontrolling interests.

⁽⁴⁾ From December 31, 2020 onwards adjustments are based on average mark-to-market timing difference. Prior adjustments are based on total Trailing 4 Quarters Mark-to-Market timing difference.



⁽²⁾ Readily Marketable Inventory attributable to merchandising is calculated as average account balance over the trailing four quarters preceding the reporting date, excluding the Sugar and Bioenergy segment.

⁽³⁾ Adjusted for certain gains & charges, mark-to-market timing difference, taxes on interest expense and RMI Adjustment.

Below is a reconciliation of Income (loss) from continuing operations before income tax to Return before income tax, adjusted, as utilized to calculate ROIC and AROIC in the preceding slides:

(US\$ in millions)	Trailing 4 Quarters 31-Mar-22	Trailing 4 Quarters 31-Dec-21	Trailing 4 Quarters 31-Dec-20	Trailing 4 Quarters 31-Dec-19	Trailing 4 Quarters 31-Dec-18
Income (loss) from continuing operations before income tax	\$2,260	\$2,565	\$1,413	(\$1,205)	\$456
Interest expense	281	243	265	339	339
Certain gains & charges, excluding Sugar & Bioenergy (1)	30	(176)	(64)	350	114
Mark-to-market timing difference	161	(8)	190	35	(4)
Sugar & Bioenergy Segment EBIT	(127)	(112)	86	1,623	135
Adjusted Return before income tax	\$2,605	\$2,512	\$1,890	\$1,142	\$1,040

⁽¹⁾ Certain gains & charges exclude certain gains and charges related to the Sugar & Bioenergy segment for all years presented and reflects 100% shareholding, i.e., including amounts attributable to noncontrolling interests.



Below is a reconciliation of Net income (loss) attributable to Bunge to Timing Adjusted EBIT, excluding notables

	Trailing 4				
	Quarters	Quarters	Quarters	Quarters	Quarters
	31-Mar-21	31-Dec-21	31-Dec-20	31-Dec-19	31-Dec-18
(US\$ in millions)					
Net Income (loss) attributable to Bunge	\$1,934	\$2,078	\$1,145	(\$1,280)	\$267
Interest income	(48)	(48)	(22)	(31)	(31)
Interest expense	281	243	265	339	339
Income tax expense	314	398	248	86	179
Income from discontinued operations, net of tax	-	-	-	-	(10)
Noncontrolling interests' share of interest and tax	(13)	(10)	(3)	(5)	(7)
Total Segment EBIT from continuing Operations	\$2,468	\$2,661	\$1,633	(\$891)	\$737
Certain gains & charges	30	(123)	(64)	2014	144
Mark to market timing difference	161	(8)	190	35	(4)
Timing Adjusted EBIT, excluding notables	\$2,659	\$2,530	\$1,759	\$1,158	\$877



Below is a continuation of the reconciliation of Net income (loss) attributable to Bunge to Timing Adjusted EBIT, excluding notables and Timing Adjusted EPS, excluding notables

	Trailing 4				
	Quarters	Quarters	Quarters	Quarters	Quarters
(US\$ in millions)	31-Mar-22	31-Dec-21	31-Dec-20	31-Dec-19	31-Dec-18
Total segment EBIT from continuing operations	\$2,468	\$2,661	\$1,633	(\$891)	\$737
Certain gains & charges	30	(123)	(64)	2014	144
Mark-to-market timing difference	161	(8)	190	35	(4)
Timing Adjusted EBIT, excluding notables	\$2,659	\$2,530	\$1,759	\$1,158	\$877
Interest Income		48	22	31	31
Interest expense, exluding notables		(243)	(265)	(339)	(339)
Timing Adjusted Income tax expense, excluding notables		(375)	(274)	(141)	(159)
Noncontrolling interests' share of interest and tax		10	3	5	7
CPS Dividends		_	-	-	(34)
Timing Adjusted net income (loss) attributable to Bunge, excluding notables		\$1,970	\$1,245	\$714	\$383
Weighted-average common shares outstanding - diluted, adjusted		152	150	150	142
Timing Adjusted EPS, excluding notables (1)	\$14.07	\$12.93	\$8.30	\$4.76	\$2.70

⁽¹⁾ Timing Adjusted EPS, excluding Notables for the Trailing Twelve Months (TTM) ended March 31, 2022 is a non U.S. GAAP measure calculated by taking the sum of Adjusted Net income (loss) per common share – diluted, for the most recent four quarters ended March 31, 2022.



BENGE